JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from a Neutral to an Overweight rating, boosting the price target to $11 from $10. The change follows the solid results of Recursion's MEK 1/2 inhibitor, REC-4881, which showed potent effectiveness in FAP patients during the TUPELO trial. After 12 weeks of treatment, the trial showed a 43% median reduction in total polyp burden, with 75% of evaluable patients experiencing reductions. Notably, 82% of patients sustained stable decreases 12 weeks after discontinuing medication, with a median reduction of 53% from baseline. JPMorgan sees explosive potential for REC-4881 in the United States, projecting peak sales of more than $1 billion with a 60% chance of success. These clinical outcomes, as well as pharmaceutical agreements that have produced more than $500 million in milestone payments to date, have helped to confirm Recursion's AI-driven pipeline. According to the firm's study, growing patient groups, stronger penetration rates, and
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. [Yahoo! Finance]Yahoo! Finance
- Cathie Wood's ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform [Yahoo! Finance]Yahoo! Finance
- Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 11/5/25 - Beat
RXRX
Sec Filings
- 12/30/25 - Form 4
- 12/29/25 - Form 4
- 12/29/25 - Form 144
- RXRX's page on the SEC website